ClinicalTrials.gg
TerminatedNCT05667662Updated Apr 2, 2024

Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

A Phase 2 interventional study of Itraconazole Powder and Placebo in ABPA, sponsored by Pulmatrix Inc.. Terminated at 18 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by Pulmatrix Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Low enrollment

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Enrollment
1,274th of 1,353
8 · median 100
Started
2023
with 54 others
Phase 2
292 of 1,695
22 open now
Registered
1,506th of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 1,274th largest by enrollment of the 1,353 interventional ones that give a count, is one of 55 that started in 2023, is one of 292 in phase 2, and was the 1,506th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about PUR1900 as an inhaled, antifungal therapeutic for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. The main questions it aims to answer are:

  1. Is PUR1900 safe and well tolerated in adults with asthma and ABPA?
  2. Is there an effect of daily administration of PUR1900 on potential outcome measures in adults with asthma and ABPA?
  3. Is there fungal resistance to A. fumigatus?

This study includes a 28-day screening period, a 112-day (16-week) treatment period, and a 56-day (8 week) observation period.

Participants will take either 40mg of PUR1900, 20 mg of PUR1900 or Placebo for 112 days and complete an eDairy, answer questions about their asthma and complete peak respiratory flow measurements at home. They will come to the clinic approximate once a month during the treatment period and complete study assessments. At the end of the observation period participants will complete one more clinic visit. Participants who complete this study may be given the opportunity to continue on study drug in an open label extension study.

03

Conditions studied

  • ABPA

Keywords

  • Asthma
  • Allergic Bronchopulmonary Aspergillosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is a male or female, ≥18 years old at the time of signing the .
  • of ≥18.0 and \<40.0 kg/m2 at screening.
  • Has a diagnosis of asthma, as per the Global Initiative for Asthma (GINA) 2018 update
  • Has a confirmed diagnosis of ABPA, based on the modified International Society for human and Animal Mycology (ISHAM) ABPA working group 2013 and 2021 criteria including a history of or documentation at screening of serum IgE ≥ 500 IU/mL and A. fumigatus-specific IgE>0.35KUA/L, or above normal IgE antibody to A. fumigatus, or a positive immediate skin test and at least 2 of the 3 following supportive criteria: eosinophil count >500 cells/µL; A. fumigatus-specific IgG >27 mgA/L or presence of precipitating (or above normal immunoglobulin G [IgG]) antibody to A. fumigatus; consistent radiographic opacities or bronchiectasis on chest CT.
  • Is currently considered to be in one of the following stages of ABPA: Stage 2 (Response), Stage 4 (Remission), Stage 5a (Treatment-dependent ABPA), or Stage 5b (-dependent asthma).
  • At least 1 exacerbation requiring a systemic glucocorticosteroid(s) in the 12 months prior to Screening. For patients on a biologic agent, at least one exacerbation requiring a systemic glucocorticosteroid(s) must have occurred at least 3 months after the initiation of the biologic agent.
  • Has a serum IgE ≥500 IU/mL at screening.
  • Has a documented stable asthma medication regimen during the 28 days prior to the first dose of study drug ; applicable asthma medications can include but are not limited to the following: inhaled short-acting beta agonist (SABA), inhaled long-acting beta agonist (LABA), and leukotriene receptor antagonist (LTRA) use and inhaled and/or oral glucocorticosteroids. SABA use during this period should be mostly within a stable range (e.g., 2 puffs 2 to 4 times a day) and should not exceed 8 puffs a day on 2 out of 3 consecutive days.
  • Can perform a valid, reproducible spirometry test with demonstration of a prebronchodilator ≥50% of predicted normal for age, sex, race, and height at a screening visit.
  • Can demonstrate the correct inhalation technique and achieve a minimum inspiratory flow rate of 45 L/min for the use of the delivery device at screening and before dosing on Day 1.
  • Is willing and able to comply with all study procedures and assessments, including scheduled visits, drug dosing plan, study procedures, laboratory tests, and study restrictions.
  • Subjects who are sexually active, male subjects able to father a child, and female subjects of must agree to follow requirements.

Exclusion criteria

Exclusion Criteria:

  • Currently requiring medications that are sensitive substrates for -mediated metabolism or medications that are with oral itraconazole.
  • Has evidence of ventricular dysfunction, such as congestive cardiac failure ( functional class III or IV), or a history of congestive cardiac failure. N-terminal pro B-type natriuretic peptide (NT pro BNP) will be checked at screening only. A subject with a confirmed value of >400 pg/mL will not be eligible to participate.
  • Has used any systemic azole antifungal agent in the 6 weeks before first dose of study drug.
  • Has discontinued previously administered biologic agent(s) in the 3 months prior to screening.
  • Has a history of life-threatening asthma within the last 24 months, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest, and/or hypoxic seizures.
  • Has a current diagnosis of any chronic airway disease other than asthma, ABPA, or bronchiectasis believed to be related to ABPA, such as , pulmonary fibrosis, cystic fibrosis, or Churg-Strauss syndrome. A subject whose predominating clinical disease burden is related to bronchiectasis (e.g., a subject with 2 or more infective exacerbations of bronchiectasis in the past 12 months or a subject with chronic colonization with Pseudomonas aeruginosa) will be excluded. Refer to Appendix 4 for definition of bronchiectasis exacerbations.
  • Had an occurrence of bacterial, viral, or fungal infection that required systemic (oral or intravenous) antibiotics, antivirals, or antifungals within the 28 days before screening. Topical treatments, other than antifungals, are allowed.
  • Had an occurrence of asthma or ABPA exacerbations within the 28 days before screening.
  • Has the presence of hoarseness or oropharyngeal candidiasis at screening.
  • Had a major trauma or surgery within the last 28-days before screening.
  • Has a history of any clinically significant cardiovascular, renal, hepatic, or gastrointestinal disease or neurological or psychiatric disorder endocrine, immunological, or disease or other medical condition that would affect the subject's safety or confound the assessment of study endpoints as judged by the Investigator.
  • Has a history of any clinically significant drug or alcohol abuse in the past 6 months before screening, as judged by the Investigator.
  • Has current inhaled tobacco/nicotine or inhaled marijuana use or history of smoking or vaping including tobacco or marijuana within the last 6 months before screening.
  • Has a history of any clinically significant drug or alcohol abuse in the past 6 months before screening, as judged by the Investigator.
  • Has current tobacco or inhaled marijuana use or history of smoking or vaping including tobacco or marijuana within the last 6 months before screening.
  • Has a history of allergic or reaction or serious adverse reaction after dosing of itraconazole or other antifungal azoles.
  • Has a history of serious adverse reaction or known serious hypersensitivity to any of the formulation .
  • Has a positive urine test result for drugs of abuse or cotinine at screening (unless, in the opinion of the Investigator, this can be explained by the subject's current medications). Note that results that are positive for a drug of abuse or cotinine may be acceptable for drugs that have been obtained by legal means or non-inhaled tobacco/nicotine product use.
  • At screening, has (ALT) or aspartate aminotransferase (AST) >2x (ULN), white blood cell (WBC) count > 20,000 X 109/L, \<1000 cells/L, counts \<100,000 to or >500,000 X 109/L, or \<10 g/dL
  • Is a female of who is pregnant or lactating or who plans to become pregnant during the study. All female subjects must have a negative pregnancy test at screening and pre dose on Day 1. A woman is of childbearing potential unless she is either permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, bilateral tubal occlusion/ligation, endometrial ablation) or (had no menses for 12 months without an alternative medical cause).
  • Has a 12-lead demonstrating a mean corrected by the Fridericia formula (QTcF) >450 msec for a male subject or >470 msec for a female subject at screening. A repeat triplicate ECG is allowed if a mean QTcF >450 msec for males and >470 msec for females is recorded at Visit 1.
  • Has a planned or elective surgery, hospitalizations, or participation in other interventional studies any time during the study that may interfere with study logistics or safety.
  • Has donated or had a loss of greater than 400 mL of blood within the 3 months before screening.
  • Has other social, psychiatric, surgical, or medical conditions or screening laboratory abnormalities that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgement of the Investigator, would make the subject inappropriate for entry into the study.
  • Received any medical product in a clinical research study within the previous 3 months before first dose of study drug.
  • Is a study site employee, an immediate family member of a study site employee, or a Sponsor employee.
  • Has previously received PUR1900.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    PUR1900 40 mg

    4 PUR1900 (10 mg itraconazole) Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients) administered via oral inhalation, using the RS01 Monodose inhaler once daily for 112 days at approximately the same time each day.

    Drug: Itraconazole Powder

  • Experimental
    PUR1900 20 mg

    2 PUR1900 (10 mg itraconazole) Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients) and 2 Placebo Capsules with with 11.8 mg total powder (excipients only) administered via oral inhalation, using the RS01 Monodose inhaler once daily for 112 days at approximately the same time each day.

    Drug: Itraconazole Powder

  • Placebo comparator
    Placebo

    4 Placebo Capsules with with 11.8 mg total powder (excipients only) administered via oral inhalation, using the RS01 Monodose inhaler once daily for 112 days at approximately the same time each day.

    Drug: Placebo

Interventions

  • Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients)

    Also known as: PUR1900

  • DrugPlacebo

    Capsules with 11.8 mg total powder (excipients only)

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Review of TEAEs from time of consent to study completion.

    Time frame: 168 days

  2. Safety spirometry assessments

    FEV1 (the volume of air (in liters) exhaled in the first second during forced exhalation after maximal inspiration), FVC (liters), and PEFR (L/min) measurements compared to baseline.

    Time frame: 168 days

  3. Vital sign measurements

    Vital signs measurements collected before exposure, during and after treatment and compared to baseline. Vital sign measurements will include respiratory rate (bpm), blood pressure (mmHg), heart rate (bpm), oxygen saturation (by pulse oximetry), and oral or tympanic temperature (°C).

    Time frame: 168 days

  4. Physical examinations

    At screening, a complete physical examination will be performed which includes measurement of height (cm), weight (kg) and evaluation of appearance; skin; head and neck; eyes, ears, nose, and throat; chest and lungs; heart; abdomen; neurological system; and extremities.

    Time frame: 168 Days

  5. Clinical safety laboratory test results

    Hematology, serum chemistry, or urinalysis test results (normal, abnormal, clinical significance) compared to baseline.

    Time frame: 168 days

  6. Cardiac safety monitoring

    Electrocardiogram (ECG) recordings collected before exposure, during and after treatment. Electrocardiogram measurements will include heart rate and PR, RR, QRS, and QT intervals, as well as the QTcF and compared to baseline.

    Time frame: 168 days

Secondary outcomes

  1. Magnitude of effect of daily administration of PUR1900 - Spirometry

    Changes in measured Forced Expiratory Volume (FEV1) over time compared to baseline

    Time frame: 168 days

  2. Magnitude of effect of daily administration of PUR1900 - Patient Reported Outcomes (ACQ)

    Responses to the Asthma Control Questionnaire (ACQ) sored from 0-6 with 0 being totally controlled and 6 being extremely poorly controlled compared to baseline.

    Time frame: 168 days

  3. Magnitude of effect of daily administration of PUR1900 - Patient Reported Outcomes (AQLQ(s) 12+)

    Responses to the Asthma Quality of Life Questionnaire with scores ranging 1-7 and higher scores indicating better quality of life compared to baseline.

    Time frame: 168 days

  4. Frequency of asthma exacerbations versus baseline

    Occurrence of asthma exacerbations before, during, and after treatment with PUR1900

    Time frame: 168 days

Other outcomes

  1. Fungal resistance to Aspergillus fumigatus

    Fungal susceptibility of sputum samples collected at the before and after anti-fungal treatment to determine resistance risks using the EUCAST microdilution method

    Time frame: 168 days

07

Study locations

18 sites
  • University of Alabama Medical Center at Birmingham
    Birmingham, Alabama 35233, United States
  • Medical Research of Arizona
    Scottsdale, Arizona 85251, United States
  • Jonathan Corren, MD
    Santa Monica, California 90025, United States
  • Bensch Clinical Research
    Stockton, California 95207, United States
  • Southern Illinois University Center for Clinical Research
    Springfield, Illinois 62702, United States
  • University of Kansas Medical Center Research Institute
    Kansas City, Kansas 66160, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • UTMB Health
    Galveston, Texas 77555, United States
  • Westmead Hospital
    Westmead, New South Wales NSW 2145, Australia
  • Mater Hospital Brisbane, Respiratory Research Group
    South Brisbane, Queensland QLD 4101, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • CHU Pontchaillou
    Rennes, Cedex 9 35033, France
  • Nouvel Hôpital Civil
    Strasbourg, Strasbourg Cedex 67091, France
  • CHU de Marseille Hôpital Nord
    Marseille, 13015, France
  • University Hospitals Birmingham - Heartlands Hospital
    Birmingham, West Midlands B9 5SS, United Kingdom
  • CPS Research Limited
    Glasgow, G20 7BE, United Kingdom
  • Royal Brompton Hospital
    London, SW3 6HP, United Kingdom
  • University Hospital of South Manchester - Wythenshawe Hospital,
    Manchester, M23 9LT, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Feb 2024, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2022
First posted
Dec 28, 2022
StartActual
Feb 1, 2023
Primary completionActual
Feb 27, 2024
CompletionActual
Feb 27, 2024
Last update
Apr 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05667662
Lead sponsor
Pulmatrix Inc.
Responsible party
Sponsor
First posted
Dec 28, 2022
Start date
Feb 1, 2023
Primary completion
Feb 27, 2024
Completion
Feb 27, 2024
Last update
Apr 2, 2024

Study contacts

Chris Cabell, MD
study director · Pulmatrix Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itraconazole

Start the discussion